Innate Pharma and Transgene: creation of Platine Pharma Services
11 May 2011
Innate Pharma and Transgene, two biotechnology companies specialized in the development of innovative immuno therapeutics, announced on 4th May 2011 the creation of Platine Pharma Services ("Platine").
The monitoring and characterization of an immune response
Platine is a new immunomonitoring company providing fee-based services to the healthcare industry for the preclinical and clinical development of prophylactic and therapeutic drug candidates, notably those with immune modulation activity such as vaccines, monoclonal antibodies or cytokines. Platine is owned equally by Innate Pharma and Transgene.
Immunomonitoring consists in the monitoring (cellular, molecular, biochemical) and characterization of an immune response after a given treatment. It is a very important step for the defining of the pharmacodynamic effect, the mechanistic properties, the therapeutic target or the safety profile of a drug candidate.
Platine, created on the basis of a program supported by the Lyonbiopole cluster
The creation of Platine originates from the will of Innate Pharma and Transgene to pool internal resources and costs incurred for their own immunomonitoring needs.
A collaborative program was set up in 2008 by the two partners, together with academic laboratories (Inserm and Centre Léon-Bérard, Lyon, France) and Grenoble-based ImmunID.
This program was supported by the Lyonbiopole cluster and benefited from local and national public funding. A team and a platform of services were put together during the three-year of collaborative work. Services rendered to Innate Pharma and Transgene for their own preclinical and clinical use enabled the building and validation of a sound expertise in the field of immunomonitoring.
"With Platine, Innate Pharma and Transgene combine 40 years of expertise in the field of immunotherapeutics and measure of cellular response. As founders and first clients, we are convinced of the relevance and added-value of Platine", said Hervé Brailly, CEO of Innate Pharma. Philippe Archinard, Chairman and CEO of Transgene, added: "We would like to thank all the collaborative partners as well as the public funding bodies which contributed to the creation of Platine. It is now up to Platine's team to continue to deliver".
Becoming a European leader in preclinical and clinical immunomonitoring
Based in Lyon, in the cluster for infectious diseases, Platine offers flexible and integrated services, from advisory to set up of immunomonitoring, routine or "taylor made", tests.
The company starts with a dozen employees and three platforms in biochemistry, cellular and molecular biology as well as a comprehensive panel of equipment, including flow cytometry, ELISPOT and ELISA. For its founders and first clients, Innate Pharma and Transgene, Platine currently runs immunomonitoring services for IPH 21, a monoclonal antibody program developed by Innate Pharma, and for TG4040, a therapeutic vaccine developed by Transgene.
Jacques Berger, previously President of Sanofi-Pasteur France, independent Chairman of the Board of Platine Pharma Services, said: "With a broad, proven offer, we aim at becoming a European leader in immunomonitoring. We can respond to requests for specific as well as routine tests, from the definition of analytical needs to data analysis. This is a high value added offer in the context of a still fragmented European market".
Find out more
Platine focuses on the European market, which is estimated to be in the region of 100-200 million euros, growing at 15% per annum. The growth drivers of the market are the increasing number of products being developed as well as the trend towards outsourcing of this activity by biopharmaceutical players.